Sugi Predict

Sugi Predict / Targets / ERN1

ERN1

Serine/threonine-protein kinase/endoribonuclease IRE1 · O75460 · ERN1 on Sugi Atlas →

111,771 patent compounds predicted against ERN1, 62,751 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL118908 SCHEMBL118908 0.68 18/20
SCHEMBL118849 SCHEMBL118849 0.64 16/20
SCHEMBL59679 SCHEMBL59679 0.48 16/20
SCHEMBL59680 SCHEMBL59680 0.48 16/20
SCHEMBL59275 SCHEMBL59275 0.48 15/20
SCHEMBL117649 SCHEMBL117649 0.57 12/20
SCHEMBL36835 SCHEMBL36835 0.61 11/20
SCHEMBL57817 SCHEMBL57817 0.49 11/20
SCHEMBL90880 SCHEMBL90880 0.47 11/20
SCHEMBL58174 SCHEMBL58174 0.47 10/20
SCHEMBL58540 SCHEMBL58540 0.47 10/20
SCHEMBL125970 SCHEMBL125970 0.61 9/20
SCHEMBL42333 SCHEMBL42333 0.59 9/20
SCHEMBL59368 SCHEMBL59368 0.57 9/20
SCHEMBL59114 SCHEMBL59114 0.47 9/20
SCHEMBL59264 SCHEMBL59264 0.47 9/20
SCHEMBL16004 SCHEMBL16004 1.00 8/20
5-Bromosalicylaldehyde 5-Bromosalicylaldehyde (SCHEMBL79219) 1.00 8/20
SCHEMBL120483 SCHEMBL120483 0.49 8/20
SCHEMBL57574 SCHEMBL57574 0.48 8/20

Clinical trials — most relevant to ERN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions PHASE4UNKNOWN
Ivermectin and Nitazoxanide Combination Therapy for COVID-19 PHASE2/PHASE3UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula PHASE2COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer PHASE2COMPLETED
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor PHASE2RECRUITING
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Diagnosis of Inflammatory Bowel Disease nanNOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Effect of Protein on Endoplasmic Reticulum Stress nanNOT_YET_RECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Mitoquines in COPD nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ERN1 binder may also engage these)

ProteinNameSimilarity
Q9EQY0 — 1.000 Q9EQY0 →
Q9Z2R9 — 0.992 Q9Z2R9 →
Q09499 — 0.990 Q09499 →
Q7XIT1 — 0.990 Q7XIT1 →
Q7Z3E5 — 0.990 Q7Z3E5 →
Q9C5S2 — 0.989 Q9C5S2 →
Q3UMY5 — 0.988 Q3UMY5 →
A5D791 — 0.988 A5D791 →
P97874 — 0.988 P97874 →
Q008S8 — 0.988 Q008S8 →
Q58CP9 — 0.988 Q58CP9 →
Q761X5 — 0.988 Q761X5 →
Q91VB4 — 0.988 Q91VB4 →
P70600 — 0.987 P70600 →
Q93VJ2 — 0.987 Q93VJ2 →
O61307 — 0.987 O61307 →
O18738 — 0.987 O18738 →
Q6GM53 — 0.987 Q6GM53 →
Q6PJI9 — 0.987 Q6PJI9 →
Q91YN0 — 0.987 Q91YN0 →
Q8C0M0 — 0.987 Q8C0M0 →
Q5SNQ7 — 0.986 Q5SNQ7 →
A0A2R8QPS5 — 0.986 A0A2R8QPS5 →
B2GUY1 — 0.986 B2GUY1 →
Q6P1Y8 — 0.986 Q6P1Y8 →
Q16760 — 0.986 Q16760 →
Q9Z2B5 — 0.986 Q9Z2B5 →
Q9D2K4 — 0.986 Q9D2K4 →
A0JMD0 — 0.986 A0JMD0 →
Q8VIJ5 — 0.986 Q8VIJ5 →